Option Care Health downgraded by Jefferies with a new price target
$OPCH
Medical/Nursing Services
Health Care
Jefferies downgraded Option Care Health from Buy to Hold and set a new price target of $26.00 from $38.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/30/2025 | $40.00 | Neutral → Buy | UBS |
| 1/23/2025 | $26.00 → $35.00 | Hold → Buy | Jefferies |
| 1/13/2025 | $26.00 → $33.00 | Neutral → Buy | BofA Securities |
| 12/5/2024 | $26.00 | Neutral | UBS |
| 11/4/2024 | $27.00 | Buy → Neutral | Goldman |
| 10/31/2024 | $38.00 → $26.00 | Buy → Hold | Jefferies |
| 10/30/2024 | $43.00 → $29.00 | Buy → Neutral | BofA Securities |
| 7/16/2024 | $36.00 | Mkt Outperform | JMP Securities |
SCHEDULE 13G/A - Option Care Health, Inc. (0001014739) (Subject)
10-Q - Option Care Health, Inc. (0001014739) (Filer)
8-K - Option Care Health, Inc. (0001014739) (Filer)
Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an
Provides access to broad-reaching nationwide network of specialty pharmacy and ambulatory infusion suites across the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has formed a strategic relationship with Option Care Health, Inc. (NASDAQ:OPCH), the nation's largest independent provider of home and ambulatory infusion services, to support the commercial development and efficient launch of Quince's lead asset, encapsulated dexamethasone sodium phosphate (eDSP) in the U.S., assuming positive study results and subsequent regulatory approval.
BANNOCKBURN, Ill., July 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenue of $1,416.1 million, up 15.4% compared to $1,227.2 million in the second quarter of 2024Gross profit of $269.0 million, or 19.0% of net revenue, up 7.9% compared to $249.4 million, or 20.3% of net revenue, in the second quarter of 2024Net income of $50.5 million, compared to net income of $53.0 million, in the second quarter of 20
Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
New Board Brings Significant and Diverse Experience to Support Company's Growth and Success Riverbed|Aternity (the "Company") today announced that, as part of its recapitalization, which was finalized today, the following seven directors have been appointed to the Company's new Board of Directors (the "Board"). These appointments became effective on December 7, 2021, upon the completion of the Company's recapitalization and voluntary court-supervised process. "We are pleased to welcome our new directors, a group of seasoned, accomplished and respected business leaders who will bring a wide and diverse range of skills to the Riverbed|Aternity Board," said Dan Smoot, President and CEO of Ri
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
UBS upgraded Option Care Health from Neutral to Buy and set a new price target of $40.00
Jefferies upgraded Option Care Health from Hold to Buy and set a new price target of $35.00 from $26.00 previously
BofA Securities upgraded Option Care Health from Neutral to Buy and set a new price target of $33.00 from $26.00 previously
BANNOCKBURN, Ill., July 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenue of $1,416.1 million, up 15.4% compared to $1,227.2 million in the second quarter of 2024Gross profit of $269.0 million, or 19.0% of net revenue, up 7.9% compared to $249.4 million, or 20.3% of net revenue, in the second quarter of 2024Net income of $50.5 million, compared to net income of $53.0 million, in the second quarter of 20
BANNOCKBURN, Ill., June 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its second quarter ended June 30, 2025 on Wednesday, July 30, 2025 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call DetailsParticipants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BI6761a41f2d314134ba5d574509278b8d. The call can also be accessed via a liv
BANNOCKBURN, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Net revenue of $1,333.0 million, up 16.3% compared to $1,146.1 million in the first quarter of 2024Gross profit of $263.1 million, or 19.7% of net revenue, up 10.3% compared to $238.5 million, or 20.8% of net revenue, in the first quarter of 2024Net income of $46.7 million, compared to net income of $44.8 million, in the first quarter of 2024 and diluted
SC 13G - Option Care Health, Inc. (0001014739) (Subject)
SC 13G/A - Option Care Health, Inc. (0001014739) (Subject)
SC 13G/A - Option Care Health, Inc. (0001014739) (Subject)